S.Biomedics Co., Ltd. (KOSDAQ:304360)
31,450
+1,650 (5.54%)
At close: Jun 12, 2026
S.Biomedics Revenue
S.Biomedics had revenue of 4.40B KRW in the quarter ending March 31, 2026, a decrease of -1.45%. This brings the company's revenue in the last twelve months to 16.48B, up 5.73% year-over-year. In the year 2025, S.Biomedics had annual revenue of 16.55B with 20.49% growth.
Revenue (ttm)
16.48B
Revenue Growth
+5.73%
P/S Ratio
23.63
Revenue / Employee
n/a
Employees
n/a
Market Cap
389.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.55B | 2.81B | 20.49% |
| Dec 31, 2024 | 13.73B | 625.65M | 4.77% |
| Dec 31, 2023 | 13.11B | 995.73M | 8.22% |
| Dec 31, 2022 | 12.11B | 3.24B | 36.58% |
| Dec 31, 2021 | 8.87B | 3.55B | 66.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 110.50B |
| NIBEC | 32.34B |
| Genome & Company | 24.02B |
| Kangstem Biotech | 3.42B |
| Inventage Lab | 3.16B |
| Y-Biologics | 2.79B |
| IntoCell | 2.47B |
| curacle co.,ltd. | 1.06B |